Announcement Under Regulation 30 (LODR): Investor Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aptus Pharma Ltd, a BSE SME listed pharmaceutical company established in 2010, has released an investor presentation showcasing strong financial performance. For FY 2025-26, revenue doubled to Rs 4,670.81 lakh (up 89.59% YoY), with EBITDA at Rs 750.32 lakh and PAT at Rs 461.99 lakh. The company operates an asset-light model with 250+ formulations across 15+ therapeutic segments, serving 10K+ doctors through 200+ distributors and 50K+ retailers. The presentation outlines an expansion strategy including a new Mindcare division for neuro-psychiatric therapies, APTUS Orbit franchise model for pan-India expansion, backward integration into manufacturing (nutraceuticals/cosmeceuticals), and export subsidiary targeting Latin America, Africa, and Asia markets. The company recently announced a 3:2 bonus share issue and received clean CARE Ratings report confirming IPO proceeds utilization as planned.
Strong revenue growth and clear multi-year expansion roadmap signals positive momentum. The planned pan-India expansion through direct and franchise models, along with export entry and backward integration into manufacturing, could drive continued growth. However, investors should note this is a small-cap BSE SME company with limited public financial history.